Format

Send to:

Choose Destination
See comment in PubMed Commons below
Neuropharmacology. 2011 Jun;60(7-8):1187-92. doi: 10.1016/j.neuropharm.2010.10.025. Epub 2010 Oct 31.

Huntington's disease is a disorder of the corpus striatum: focus on Rhes (Ras homologue enriched in the striatum).

Author information

  • 1Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA. ssnyder@jhmi.edu

Abstract

Despite identification of the gene for huntingtin (Htt) as causal in Huntington's Disease (HD), explication of HD symptoms and selective damage to the corpus striatum has been elusive. The small G protein Rhes Ras homolog enriched in striatum, highly localized to the striatum, binds selectively to mutant Htt (mHtt) and enhances sumoylation of mHtt. Sumoylation disaggregates mHtt and augments its cytotoxicity. Thus, it appears likely that Rhes-mHtt interaction accounts in substantial part for the selective striatal neurotoxicity of HD with associated extrapyramidal symptomatology. Rhes also binds and activates mTOR, enhancing its influence on protein synthesis, and may be the principal determinant of striatal mTOR activation. In HD, sequestration of Rhes by mHtt may decrease its access to mTOR. The attendant loss of protein translational stimulation may explain the pronounced striatal atrophy of HD. This article is part of a Special Issue entitled 'Trends in neuropharmacology: in memory of Erminio Costa'.

Copyright © 2010. Published by Elsevier Ltd.

PMID:
21044641
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk